VANCOUVER, British Columbia, July 16, 2024 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the “Company” or…
Testing confirms MIRA's preliminary beliefs regarding potential treatment for neurological and neuropsychiatric disorders MIAMI, FL / ACCESSWIRE / July 15,…
PLEASANTON, Calif., July 12, 2024 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, today…
NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES VANCOUVER, British Columbia, July 11, 2024…
Funded by a nearly £1.2M (~$1.5M USD) award, this research will enable ongoing validation of AccelADx™, a breakthrough screening test for…
Phase 2b RewinD-LB trial of neflamapimod for the treatment of dementia with Lewy bodies is fully enrolled with topline data…
NeuroStar, the first and only TMS treatment cleared for adolescents, now covered by Medi-CalMALVERN, Pa., July 11, 2024 (GLOBE NEWSWIRE)…
Exclusive global rights secured for development, manufacture and commercialization of FS001, completing final stages of pre-clinical development with first-in-class potentialFS001…
Pragmatic registry provides high-quality real-world data on Alzheimer's disease, dementia, and mild cognitive impairment for research PALO ALTO, Calif. , July 10,…
The Fresh Start Award Program will grant up to five individuals a one-time prize of $10,000 to help them reach…